HPLC method for simultaneous determination of cefprozil diastereomers in human plasma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tae-Hwan Park | - |
dc.contributor.author | Jin-Ki Kim | - |
dc.contributor.author | Jun-Pil Jee | - |
dc.contributor.author | Jeong-Sook Park | - |
dc.contributor.author | Chong-Kook Kim | - |
dc.date.accessioned | 2021-06-24T00:39:16Z | - |
dc.date.available | 2021-06-24T00:39:16Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2004-09 | - |
dc.identifier.issn | 0731-7085 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/46557 | - |
dc.description.abstract | A high-performance liquid chromatography method was developed for the determination of cefprozil diastereomers in human plasma. Cefprozil exists as cis and trans isomer at the ratio of 90:10. Plasma samples were prepared by protein precipitation using acetonitrile, trichloroacetic acid and methylene chloride. After the mixtures were vortexed and centrifuged, the aqueous supernatant was injected into a reversed-phase C-8 column. The mobile phase consisted of acetonitrile, glacial acetic acid and distilled water at the volume ratio of 5.5:1.75:92.75 (pH 2.7). The signals were monitored with UV detection at 280 nm. The calibration curves of cis and trans isomer were linear in concentration ranges of 0.1-25 and 0.02-2.5 mug/mL with the correlation coefficient of 0.9999 and 0.9989, respectively. After oral administration of cefprozil in humans, C-max and T-max of total cefprozil were 18.80 +/- 2.14 mug/mL and 2.06 +/- 0.62 h. This method was sensitive with excellent selectivity and reproducibility, and successfully applied to a bioavailability study of cefprozil in healthy subjects. (C) 2004 Elsevier B.V. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | HPLC method for simultaneous determination of cefprozil diastereomers in human plasma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jin-Ki Kim | - |
dc.identifier.doi | 10.1016/j.jpba.2004.06.001 | - |
dc.identifier.scopusid | 2-s2.0-4444302855 | - |
dc.identifier.wosid | 000224328000033 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, v.36, no.1, pp.243 - 248 | - |
dc.relation.isPartOf | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | - |
dc.citation.title | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS | - |
dc.citation.volume | 36 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 243 | - |
dc.citation.endPage | 248 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ORAL CEPHALOSPORIN | - |
dc.subject.keywordPlus | INVITRO ACTIVITY | - |
dc.subject.keywordPlus | BMY-28100 | - |
dc.subject.keywordPlus | CEFACLOR | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordAuthor | cefprozil | - |
dc.subject.keywordAuthor | stereoisomer | - |
dc.subject.keywordAuthor | cis | - |
dc.subject.keywordAuthor | trans | - |
dc.subject.keywordAuthor | HPLC | - |
dc.subject.keywordAuthor | pharmacokinetic studies in human | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0731708504002523?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.